Accelerating Drug Development Using Biomarkers: A Case Study with Sitagliptin, A Novel DPP4 Inhibitor for Type 2 Diabetes

This publication has 45 references indexed in Scilit:

• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
  Diabetologia, 2006
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
  Published by Elsevier ,2006
• Recent evidence of sustained benefit with exenatide in Type 2 diabetes
  Expert Opinion on Pharmacotherapy, 2006
• US and European regulatory initiatives to improve R&D performance
  Expert Opinion on Drug Discovery, 2006
• Introduction to Dose Optimization in Drug Development
  Published by Taylor & Francis ,2006
• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
  Clinical Therapeutics, 2006
• The ultimate model organism: progress in experimental medicine
  Nature Reviews Drug Discovery, 2005
• Can the pharmaceutical industry reduce attrition rates?
  Nature Reviews Drug Discovery, 2004
• Global and societal implications of the diabetes epidemic
  Nature, 2001
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
  Clinical Pharmacology & Therapeutics, 2001